
-
Rigel Pharmaceuticals NasdaqGS:RIGL Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Location: 611 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.rigel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
378.4M
Cash
77.1M
Avg Qtr Burn
N/A
Short % of Float
12.37%
Insider Ownership
2.59%
Institutional Own.
78.35%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REZLIDHIA (Olutasidenib) (FT-2102) Details Cancer, Acute myeloid leukemia | Approved Quarterly sales | |
TAVALISSE® (fostamatinib disodium hexahydrate) Details Adult Chronic Immune Thrombocytopenia (ITP) | Approved Quarterly sales | |
GAVRETO (pralsetinib) Details Non-small cell lung carcinoma | Approved Quarterly sales | |
REZLIDHIA (Olutasidenib) (FT-2102) Details Glioma, Acute myeloid leukemia, Cancer | Approved Quarterly sales | |
Phase 3 Data readout | ||
REZLIDHIA (Olutasidenib) (FT-2102)+ temozolomide Details Glioma, Cancer | Phase 2 Initiation | |
R552 Details Rheumatoid arthritis, Autoimmune disease | Phase 2a Data readout | |
REZLIDHIA (Olutasidenib) [triplet therapy] Details Cancer, Acute myeloid leukemia | Phase 1/2 Data readout | |
R289 Details Lower-risk myeloid dysplastic syndrome | Phase 1b Data readout | |
TAVALISSE® (fostamatinib disodium hexahydrate) Details Blood disorder | Failed Discontinued | |
Failed Discontinued |